Welcome

The 8th EurAsian Uro-oncology Congress (EUA18) will be held from June 28th to July 1st, 2018 in Tbilisi, Georgia. EUA has been issuing wide range of topics over the years. This EUA18 provides a forum for presenting original unpublished data and sharing ideas for urological innovation. Although the main topic of EUA18 will be prostate and renal cancer, contemporary management of other urological malignancies will also be discussed.

Urologists, medical oncologists and affiliated professionals attending the EUA18 will be able to review innovative techniques and scientific advances in the field of urological oncology, especially on prostate and renal cancer. They will also find the chance to communicate, collaborate and network with representatives of a large international audience – medical professionals and national urological societies.

Perspectives

Multidisciplinary sessions -Perspectives- will run during the congress. We would like to provide a rich platform where controversial perspectives from the international societies will be analyzed on the most important uro-oncological diseases.

B2B

As the advances in genomic, proteomic and imaging technologies have led to an expansion of our understanding of cancer in general, uro-oncology knowledge and practice is also rapidly evolving. A multi-faceted collaboration among researchers, clinicians, and the industry has emerged. One of the goals of the congress is to discuss these developments in their entirety. In order to address the cutting edge research, translational medicine session will take part in the program. For this reason, the B2B (Bench to Bedside) Renal Cancer Meeting will be held on the first day of the EUA18.

Friends of Georgia

One day scientific event which was organized biannually by Georgian Urological Association and Israel Urological Association will be held during EUA18 in collaboration with EurAsian Association of Uro-oncology.

Societies of the region

Effects of the recent advancements to a specific region. Comparing the clinical governance, knowledge, attitudes and practices in Balkans, Caucasia, Middle East and Asia.

As-Live

EUA18 will feature a special session called “As-Live” for uro-oncologic surgeries.

Uro-oncology Highlights 2018

EUA has been issuing wide range of topics over the years. Although the main topic of EUA18 will be prostate and renal cancer, latest clinical advancements of other urological malignancies will be outlined during the uro-oncology highlights session.

Education & Training

The meeting will have an education and training part which includes endoscopic management, laparoscopy and robotic assisted laparoscopic procedures of uro-oncology. There also will be education and training workshops for theater nurses.

Young Urooncologists and Medical Oncologists

Unique sessions, awards and social programs for young urologists and medical oncologists will take place.

8th Eurasian Uro-oncology Congress

Official Airline

Turkish Airlines is the official airline of “8th Eurasian Uro-oncology Congress and special discounts are offered on certain booking classes. In order to proceed with the online booking tool for Turkish Conventions please visit the Turkish Conventions website https://www4.thy.com/TKC/app/main?language=en and use the event code “108TKM18” under delegate section.

Best Case Report Contest

Who can participate

Urologists representing national societies of Urology or other institutions who are the official partners of the 8th Eurasian Uro-oncology Congress.

Criteria for submission

  1. Only original case reports previously unpublished and not under consideration for publication elsewhere may be submitted.
  2. Case reports should describe an original observation concerning diagnosis, treatment or both. They should fit into one of the following categories:
    – Rare conditions.
    – Unusual presentation or complications of a relatively common condition.
    – A difficult road to diagnosis.
    – Cases of high educational value for other reasons.

Rules

1. Cases will be collected by online abstract system.
2. Academic titles should not be used in author names.
3. Summary; purpose, method, findings, conclusions and key words.
4. The abstract must not exceed 250 words, excluding the full title, title, author’s name, surname.
5. The names and addresses of the institutions in which the authors work should be clearly indicated.
Ex: Xxxx University Faculty of Medicine, Xxxx Department of Health, City
6. If an abbreviation is used in the abstract, the abbreviated name of the abbreviation should be specified in parentheses.
7. Deadline for abstract submission: 18 May 2018.

Points to Consider

– If this is the first time you will use the online notification module, you must register with the system using the “New User” link.
– After sign-up, explanations on the page will help you. Read the messages and explanations carefully.
– Keep a confirmation message to your email address after your abstract submission.
– You can follow the entire evaluation process with your email and password through your system.
– For technical support or questions during submission:
LookUs Information Services Ltd.
Tel: (0216) 372 66 44

Invited Speakers

Jean de la Rosette
Academic Medical Center University of Amsterdam, Department of Urology, The Netherlands

Ignacio Duran
Virgen del Rocio University Hospital, Department of Biological Medicine, Spain

Steven Joniau
University Hospital Leuven, Department of Urology, Belgium

Jose A. Karam
The University of Texas MD Anderson Cancer Center, Department of Urology, USA

Makarand Khochikar
Siddhi Vinayak Ganapati Cancer Hospital, India

Badrinath Konety
University of Minnesota, Department of Urology, USA

Omer Kucuk
Winship Cancer Institute of Emory University, Department of Oncology,USA

Pilar Laguna
Academic Medical Center University of Amsterdam, Department of Urology, The Netherlands

Börje Ljungberg
Head of Unit Urology and Andrology, Sweden

Aytekin Oto
The University of Chicago, Department of Urology, USA

Rajeev Sood
Dean of PGI MER & Dr RML Hospital, India

Simon Tanguay
McGill University, Department of Urologic Oncology, Canada

Dogu Teber
Heidelberg University,Department of Urology, Germany

Omer Kucuk

Omer Kucuk

Winship Cancer Institute of Emory University, Department of Oncology,USA

Omer Kucuk, MD, conducted the first clinical trials to show the benefits of soy and lycopene supplements in prostate cancer treatment.  He is a Professor in Hematology and Medical Oncology at Emory University’s Winship Cancer Institute.

Dr. Kucuk came to Emory Winship from the Karmanos Cancer Center at Wayne State University in Detroit where he was a professor and co-leader of the population sciences and prevention program and member of genitourinary and head and neck cancer multidisciplinary groups.

Dr. Kucuk has more than 200 peer-reviewed publications, review articles and book chapters to his credit, and he is on the editorial boards of numerous publications, including the Cancer Epidemiology, Biomarkers and Prevention and Cancer Epidemiology.

Nutrition and cancer is Dr. Kucuk’s primary research focus, and he has published extensively on various nutrients in combination with chemotherapy and radiation.   Dr. Kucuk has been conducting clinical trials with lycopene and soy isoflavones in combination with standard therapy for prostate cancer since 1995.   He is also investigating the effects of micronutrients and phytochemicals on biomarkers of cell growth, differentiation, inflammation and oxidative stress in a variety of cancers.

Dr. Kucuk earned his medical degree at Hacettepe University Medical School in Ankara, Turkey.  He conducted a residency and fellowship at St. Francis Hospital in Evanston, Illinois, and a hematology and oncology fellowship at Northwestern University Medical School in Chicago.  Before joining the medical staff at Wayne State University, Dr. Kucuk served as professor and researcher at the University of Hawaii’s John A. Burns School of Medicine in Honolulu.

Rajeev Sood

Rajeev Sood

Dean of PGI MER & Dr RML Hospital, India

Makarand Khochikar

Makarand Khochikar

Siddhi Vinayak Ganapati Cancer Hospital, India

Dr Makarand Khochikar qualified as a surgeon in 1988 (Miraj), completed his residency in urology in 1992 (Mumbai) and then had further training in urology, urologic oncology at Bedford and Addenbrooke’s hospital, Cambridge (UK) from 1993-1998.He returned to India in 1998 to establish a state of the art Uro-oncology unit at Siddhi Vinayak Ganapati Cancer Hospital, Miraj. This department undertakes large amount of uro-oncological work and has made its presence felt nationally and internationally.

Dr Khochikar has won many awards. Dr Kirpekar award and Gold Medal for standing first in university in Master of Surgery exam in1988, Schering Prize and a Gold medal for standing first at University of London in Dip.Urol exam in 1991, Vijayawada Best poster award and Brijkishor Patana best paper award are some of them. Recently he was awarded the highest honor of urological society of India (West Zone) – The Urology Gold Medal in 2010. Recipient of Gold Medal and SLAUS oration by Sri Lanka Urology Association in 2011. In year 2012-  he was awarded yet another prestigious award – Pinamaneni Oration and Gold medal by USI for his life time work on adrenal tumors mainly pheochromocytoma. He has one of the largest individual series on adrenal tumors in India. He was awarded the best reviewer’s award – special appreciation by Indian Journal of Urology for 2015.

He has produced many high quality original publications; review articles in peer reviewed national and international journals and contributed in book chapters.

Has been invited as a national and international faculty to many centers, has conducted large number of symposia, operative demonstrations and delivered guest lecturers across the globe. Teaching has been very close to his heart, has been conducting teaching courses on Uro-oncology since last 15 years, a weeklong crash course on Uro-oncology conducted annually at Muljibhai Patel urological hospital, Nadiyad and JPAC is the most popular course in urology in India.

He has conducted teaching courses for Asian School of Urology and SUA at Singapore, BAUS and ASU at Bangladesh, European School of Urology and ASU at Hong Kong, Malaysia, Sri Lanka and Indonesia. He has been part of AUA -USI instructional courses in India and has conducted instructional courses at SIU annual meetings. Recently he conducted a three day course on Uro-oncology at Nadiyad which was webcasted by SIU academy.

Has been invited as a guest speaker for many international meetings ( AUA ,SIU , EAU,WPCC , WUOF , BAUS ) and by international societies in Asia ( India , Sri Lanka , Bangladesh, Malaysia, Hong Kong, Singapore, Indonesia, China, Philippines, Myanmar), Japan ,Australia, UK , Germany, Italy , France, Spain , Greece ,Middle East ,UAE ,Egypt  ,USA and Canada in last twenty years.

He was the core member of the Guidelines committee that designed Indian Bladder Cancer Guidelines for Urological society of India. He was the member of the Indian panel that recommended amendments in TNM classification system for urological cancers in 2004.He was on the panel for the Melbourne Prostate Cancer statement, at WPCC meeting in Australia in 2014.

Was invited as an examiner for exit exam in urology at Singapore and for P hD at Pravara University, Pravaranagar (India)

Dr Khochikar was a member of the ICUD (International Consultation on Urologic Diseases) consultation panel for upper tract TCC supported by SIU and is also currently involved in preparing ICUD –SIU guidelines on bladder cancer .

Dr Khochikar served on editorial board of Indian Journal of Urology (2000-2009), Current Urology Reports, and peer reviewer for BJUI, Journal of Urology, Indian Journal of surgery, Indian Journal of cancer, Urology Annals, International Journal of Urology, Journal of Clinical Urology and many others. He has served as a guest editor of the special issue of IJU on hormone refractory prostate cancer. He did undertake the course for the reviewers by Journal of Urology.

He has served as a council member of Urological society of India (USI), USI-West Zone, was a core member of education cell of USI and has served as a convener of research cell of USI. He was the convener of the section of uro-oncology for the USI (2003-2007)

He is currently National delegate for the Indian section of SIU, has served as Deputy National Delegate from 2013-2015.He has been appointed as  Board of Directors of SIU in Oct 2016.

He is  currently President of the Urological society of India –West zone .

Currently he is the Chairman of the Department of Uro-oncology at Siddhi Vinayak Ganapati Cancer Hospital, Miraj and is also a member of the management committee and Governing council of the hospital.

Considered as an authority and leading surgeon in India in Nephron sparing surgery, Radical prostatectomy, and radical cystectomy with neobladder reconstruction in bladder cancer, adrenalectomies and post chemotherapy RPLND in testicular cancer.

Steven Joniau

Steven Joniau

University Hospital Leuven, Department of Urology, Belgium

Börje Ljungberg

Börje Ljungberg

Head of Unit Urology and Andrology, Sweden

Badrinath Konety

Badrinath Konety

University of Minnesota, Department of Urology, USA

Simon Tanguay

Simon Tanguay

McGill University, Department of Urologic Oncology , Canada

Jean de la Rosette

Jean de la Rosette

Academic Medical Center University of Amsterdam, Department of Urology, The Netherlands

Ignacio Duran

Ignacio Duran

Virgen del Rocio University Hospital, Department of Biological Medicine, Spain

Jose A. Karam

Jose A. Karam

The University of Texas MD Anderson Cancer Center, Department of Urology, USA

Dr. Karam is an Associate Professor of Urology at MD Anderson Cancer Center. He is certified by the American Board of Urology, and provides surgical care for patients with renal, testicular and adrenal tumors. He performs open, laparoscopic, and robotic surgery, with a special interest in surgery for locally advanced and locally recurrent disease.

Dr. Karam earned his medical degree with Distinction from the American University of Beirut. He completed Urology residency at UT Southwestern Medical Center, followed by a Urologic Oncology Fellowship at MD Anderson Cancer Center.

Dr. Karam’s primary clinical and research interest is renal cell carcinoma, including the integration of targeted therapy with surgery (adjuvant, neoadjuvant, and presurgical therapy), sarcomatoid renal cell carcinoma, rare kidney cancer histologies including renal medullary carcinoma, mouse models of renal cell carcinoma and molecular markers. He has authored more than 170 articles and book chapters in urologic oncology. He serves as a reviewer for over 20 journals, and is an Editorial Board member of BJU International, Section Editor for Annals of Surgical Oncology, and Associate Editor for Frontiers in Oncology.

Pilar Laguna

Pilar Laguna

Academic Medical Center University of Amsterdam, Department of Urology, The Netherlands

Aytekin Oto

Aytekin Oto

The University of Chicago, Department of Urology, USA

Dr. Oto is the Vice Chair for Business Development, Chief of Abdominal Imaging and Body MRI at the University of Chicago, and has a wide range of experience and expertise in the imaging of diseases affecting abdomen and pelvis. His interest focus is development and clinical application of novel prostate MRI acquisition and interpretation so as to facilitate and improve the efficiency of prostate cancer and develop image guided prostate therapy options for the appropriate patients diagnosed with prostate cancer.  His research has resulted in more than 150 publications and over 150 scientific exhibits at national and international meetings. The two overarching aims of his research are: 1) non-invasive and accurate diagnosis of aggressive prostate cancer using MR imaging; and 2) eradication of localized prostate cancer with minimal complications using minimally invasive treatment methods. Our group has already has developed new MR sequences, pilot CAD software for prostate MRI, and tested MR guided therapy methods such as laser and focused ultrasound ablation in clinical and pre-clinical studies.

Dogu Teber

Dogu Teber

Heidelberg University,Department of Urology, Germany

Faculty

Oztug Adsan
TOBB-ETU Hospital, Department of Urology, Turkey

Erdem Akbay
Mersin University Faculty of Medicine, Department of Urology, Turkey

Ziya Akbulut
Istanbul Medipol University Faculty of Medicine, Department of Urology, Turkey

Oktay Akca
U.H.S. Istanbul Kartal Dr. Lütfi Kırdar Training and Research Hospital, Department of Urology, Turkey

Farkhad Akilov
President of Scientific Society of Urology of Uzbekistan, Uzbekistan

Yigit Akin
Izmir Katip Celebi University Faculty of Medicine, Department of Urology, Turkey

Selami Albayrak
Medipol University Hospital Faculty of Medicine, Department of Urology, Turkey

Fatih Altunrende
U.H.S. Okmeydanı Training and Research Hospital, Department of Urology, Turkey

Murat Arslan
İzmir Medical Park Hospital, Department of Urology, Turkey

Yilmaz Arslan
U.H.S. Ankara Numune Training and Research Hospital, Department of Urology, Turkey

Ali Fuat Atmaca
Ankara Yildirim Beyazit University Faculty of Medicine, Department of Urology, Turkey

Khaled Attallah
President of Tunisian Urological Society, Tunisia

Fatih Atug
Istanbul Florence Nightingale Hospital, Department of Urology, Turkey

Sabahattin Aydin
Rector of Istanbul Medipol University, Turkey

Ali Ayyildiz
U.H.S. Ankara Training and Research Hospital, Department of Urology, Turkey

Hasan Bakirtas
Memorial Ankara Hospital, Department of Urology, Turkey

M. Derya Balbay
Koc University School of Medicine, Department of Urology, Turkey

Halil Basar
U.H.S. Ankara Oncology Training and Research Hospital, Department of Urology, Turkey

Abbas Basiri
President of Iranian Urological Association, Iran

Erem Kaan Basok
Izmir Medical Park Hospital, Department of Urology, Turkey

Zeki Bayraktar
Istanbul Medipol University Faculty of Medicine, Department of Urology, Turkey

Hale Caglar
Anadolu Medical Center, Department of Radiation Oncology, Turkey

Meltem Caglar Tuncalı
Hacettepe University Faculty of Medicine, Department of Nuclear Medicine, Turkey

Omer Onur Cakir
U.H.S. Bagcilar Training and Research Hospital, Department of Urology, Turkey

A. Erdem Canda
Yildirim Beyazit University Faculty of Medicine, Department of Urology, Turkey

Turhan Caskurlu
Istanbul Medeniyet University Faculty of Medicine, Department of Urology, Turkey

Mustafa Cengiz
Hacettepe University Faculty of Medicine, Department of Radiation Oncology, Turkey

Archil Chkhotua
Secretary General of Georgian Urological Association, Georgia

Jean de la Rosette
Academic Medical Center University of Amsterdam, Department of Urology, The Netherlands

Abdullah Demirtas
Erciyes University Faculty of Medicine, Department of Urology, Turkey

Ozdal Dillioglugil
Kocaeli University Faculty of Medicine, Department of Urology, Turkey

Cetin Dincel
U.H.S. Bozyaka Research and Training Hospital, Department of Urology, Turkey

Ignacio Duran
Virgen del Rocio University Hospital, Department of Biological Medicine, Spain

Selcuk Erdem
Istanbul University Faculty of Medicine, Department of Urology, Turkey

Bulent Erkurt
Istanbul Medipol University Faculty of Medicine, Department of Urology, Turkey

Cengiz Erol
Istanbul Medipol University Faculty of Medicine, Department of Radiology, Turkey

Sakıp Erturhan
Gaziantep University Faculty of Medicine, Department of Urology, Turkey

Tarik Esen
Koc University School of Medicine, Department of Urology, Turkey

Ismail Evren
U.H.S. Dr. Sadi Konuk Bakirkoy Research and Training Hospital, Department of Urology, Turkey

Arnaldo Figueiredo
Coimbra University Hospital, Department of Urology, Portugal

Cankon Germiyanoglu
Ondokuz Mayıs University Faculty of Medicine, Department of Urology, Turkey

Arthur M. Grabsky
President of Armenian Association of Urology, Armenia

Alexander Greenstein
President of Israel Urological Association, Israel

Mehmet Gulluoglu
Head of AFAD, Turkey

Eyup Gumus
Undersecretary of Republic of Turkey Ministry of Health, Turkey

Mahmut Gumus
President of Turkish Society of Medical Oncology, Turkey

Cenk Gurbuz
Medistate Hospital, Department of Urology, Turkey

Recai Gurbuz
Bezmialem Vakif University Faculty of Medicine Hospital, Department of Urology, Turkey

Zafer Gokhan Gurbuz
U.H.S. Adana Numune Training and Research Hospital, Department of Urology, Turkey

Selcuk Guven
Istanbul Medipol University Faculty of Medicine, Department of Urology, Turkey

Rahim Horuz
Istanbul Medipol University Faculty of Medicine, Department of Urology, Turkey

Musab Ilgi
U.H.S. Istanbul Sisli Hamidiye Etfal Training and Research Hospital, Department of Urology, Turkey

Abdurrahim Imamoglu
U.H.S. Diskapi Yildirim Beyazit Training and Research Hospital, Department of Urology, Turkey

Vasif Ismayil
Azerbaijan Medical University, Department of Urology, Azerbaijan

Steven Joniau
University Hospital Leuven, Department of Urology, Belgium

Levent Kabasakal
Istanbul University Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Turkey

Ates Kadioglu
Istanbul University Istanbul Faculty of Medicine, Department of Urology, Turkey

Bunyamin Kaplan
Istanbul Medipol University Faculty of Medicine, Department of Radiation Oncology, Turkey

Jose A. Karam
The University of Texas MD Anderson Cancer Center, Department of Urology, USA

M. Ihsan Karaman
Rector of Istanbul Medeniyet University, Turkey

Mehmet Kaynar
Selcuk University Faculty of Medicine, Department of Urology, Turkey

Sarp Korcan Keskin
Bahcesehir University School of Medicine, Department of Urology, Turkey

Bekir Keskinkilic
Turkish Public Health Institution, Vice President, Turkey

Mansur Khalilov
Azerbaijan Medical University, Department of Urology, Azerbaijan

Makarand Khochikar
Siddhi Vinayak Ganapati Cancer Hospital, India

Murat Can Kiremit
Koc University Hospital, Department of Urology, Turkey

Esengul Kocak
Medipol University Hospital, Department of Radiation Oncology, Turkey

Izzet Kocak
Adnan Menderes University Faculty of Medicine, Department of Urology, Turkey

Badrinath Konety
University of Minnesota, Department of Urology, USA

Fatih Kose
Baskent University Faculty of Medicine, Department of Medical Oncology, Turkey

Eyup Veli Kucuk
U.H.S. Umraniye Training and Research Hospital, Department of Urology, Turkey

Omer Kucuk
Winship Cancer Institute of Emory University, Department of Oncology, USA

Ali Riza Kural
President of Endourological Society, Turkey

Pilar Laguna
Academic Medical Center University of Amsterdam, Department of Urology, The Netherlands

Börje Ljungberg
Head of Unit Urology and Andrology, Sweden

Ahmet Yaser Muslumanoglu
Director of U.H.S. Bağcılar Training and Research Hospital, Turkey

Ismet Nane
Istanbul University Istanbul Faculty of Medicine, Department of Urology, Turkey

Janek Nawrocki
Haywards Heath Hospital, Department of Urology, England

Baris Nuhoglu
Istanbul Yeni Yuzyil University Faculty of Medicine, Department of Urology, Turkey

Oner Odabas
U.H.S. Turkiye Yuksek Ihtisas Training and Research Hospital, Department of Urology, Turkey

Tayfun Oktar
Istanbul University Istanbul Faculty of Medicine, Department of Urology, Turkey

Aytekin Oto
The University of Chicago, Department of Radiology, USA

Kubra Ozgok
U.H.S. Gulhane Research and Training Hospital, Department of Underwater Medicine, Turkey

Yasar Ozgok
President of ILRSA, Turkey

Mustafa Ozguroglu
Istanbul University Cerrahpasa Faculty of Medicine, Department of Medical Oncology, Turkey

Mehmet Serkan Ozkent
Necmettin Erbakan University Meram Faculty of Medicine, Department of Urology, Turkey

Ahmet Ozturk
Necmettin Erbakan University Meram Faculty of Medicine, Department of Urology, Turkey

Emre Can Polat
U.H.S. Okmeydani Training and Research Hospital, Department of Urology, Turkey

Iraklis Poulias
President of Hellenic Urological Association, Greece

Mohammad Hadi Radfar
Shahid Beheshti University of Medical Sciences Labbafinejad Hospital, Department of Urology, Iran

Esra Saglam
Memorial Sisli Hospital, Department of Radiation Oncology, Turkey

Selcuk Sahin
U.H.S. Dr. Sadi Konuk Training and Research Hospital, Department of Urology, Turkey

M. Oner Sanli
Istanbul University Faculty of Medicine, Department of Urology, Turkey

M. Selcuk Silay
Istanbul Medeniyet University Faculty of Medicine, Department of Urology, Turkey

Atilla Semercioz
U.H.S. Bagcilar Training and Research Hospital, Department of Urology, Turkey

Bulat Shalekenov
Chairman of Kazakhstan Association of Men’s Health, Kazakhstan

Abdul Naser Shunaigat
President of Jordanian Association of Urological Surgeons, Jordan

Giray Sonmez
Necmettin Erbakan University Faculty of Medicine, Department of Urology, Turkey

Rajeev Sood
Dean of PGI MER & Dr RML Hospital, India

Tarkan Soygur
Ankara University Faculty of Medicine, Department of Urology, Turkey

Mustafa Soytas
U.H.S. Dr. Sadi Konuk Training and Research Hospital, Department of Urology, Turkey

Simon Tanguay
McGill University, Department of Urologic Oncology , Canada

Ali Ihsan Tasci
Dean of University of Health Sciences Faculty of Medicine, Turkey

Dogu Teber
Heidelberg University, Department of Urology, Germany

Dilek Telci
Yeditepe University Faculty of Engineering, Genetics and Bioengineering Department, Turkey

Ilter Tufek
Acibadem Maslak Hospital, Department of Urology, Turkey

Volkan Tugcu
U.H.S. Dr. Sadi Konuk Bakirkoy Research and Training Hospital, Department of Urology, Turkey

Lutfi Tunc
Gazi University Faculty of Medicine, Department of Urology, Turkey

Omer Levent Tuncay
Pamukkale University Faculty of Medicine, Department of Urology, Turkey

Altug Tuncel
U.H.S. Ankara Numune Training and Research Hospital, Department of Urology, Turkey

Ahmet Tuncay Turgut
Hacettepe University Faculty of Medicine, Department of Radiology, Turkey

Kadir Turkolmez
Ankara University Faculty of Medicine, Department of Urology, Turkey

Taha Ucar
Istanbul Medeniyet University Faculty of Medicine, Department of Urology, Turkey

Dogan Unal
U.H.S. Ankara Oncology Training and Research Hospital, Department of Oncology, Turkey

Ali Unsal
Gazi University Faculty of Medicine Hospital, Department of Urology, Turkey

Ahmet Urkmez
U.H.S. Haydarpasa Numune Training and Research Hospital, Department of Urology, Turkey

Akilbek Cholponkulovich Usupbaev
President of Urology Association of Kyrgyzstan, Kyrgyzstan

Omer Erol Uzel
Istanbul Medipol University Faculty of Medicine, Department of Radiation Oncology, Turkey

Onder Yaman
Ankara University Faculty of Medicine, Department of Urology, Turkey

Ismet Yavascaoglu
Uludag University Medical Faculty, Department Chair, Department of Urology, President of the Endourology Society, Turkey

Faruk Yencilek
Yeditepe University Faculty of Medicine, Department of Urology, Turkey

Asif Yildirim
Istanbul Medeniyet University Faculty of Medicine, Department of Urology, Turkey

Ugur Yucetas
U.H.S. Istanbul Training and Research Hospital, Faculty of Urology, Turkey

Emrah Yuruk
U.H.S. Bagcilar Training and Research Hospital, Department of Urology, Turkey

Scientific Program

June 28th, 2018

Friends of Georgia

Location: Main Hall

08.00 – 10.15 Bladder Cancer – Part I
08.00 – 08.15 Incidence and mortality of bladder cancer in the world.
08.15 – 08.45 Genomic classification of bladder cancer
– NMIBC 
– MIBC
08.45 – 09.00 Optical enhancement of NMIBC: An update
09.00 – 09.15 BCG failures: Definitions, management, outcomes
09:15 – 09.30 Follow-up in non-muscle invasive bladder cancer: What is the ideal?
09.30 – 09.45 Gender specific differences in bladder cancer
 
09.45 – 10.15 Panel: Challenging cases in bladder cancer
 
10.15 – 10.30 Coffee Break
 
10.30 – 12.15 Bladder cancer – Part II
10.30 – 11.00 Minimally invasive radical cystectomy: It is worth to do?
– Yes
– No
11.00 – 11.15 The potential role of sex steroids and their specific receptors in bladder cancer
11.15 – 11.30 Frailty and bladder cancer
11.30 – 12.00 Systemic treatment in metastatic disease
– Chemotherapy
– Immunotherapy
11.30 – 11.45 The role of surgery in metastatic bladder cancer
 
11.45 – 12.15 Panel: Challenging cases in bladder cancer
 
12.15 – 13.15 Lunch

 

B2B Renal Cancer

Location: Main Hall

13.15 – 14.50 Mechanism and Biology- Prevention and Diagnosis
13.15 – 13.20 Introduction
13.20 – 13.35 Integrative design for cancer prevention and therapy
13.35 – 13.50 Rationale for renal biopsy
13.50 – 14.05 Implications of next generation sequencing for renal cancer – Liquid biopsy
14.05 – 14.20 Novel diagnostics and surgical interventions – Clinical Integration and Translation
14.20 – 14.35 Frequent incidental diagnosis of small indolent cancers -active surveillance-
14.35 – 14.50 Cystic tumors- challenges
 
14.50 – 15.15 Coffee Break
 
15.15 – 17.15 Biology and Engineering- Diagnosis and Treatment
15.15 – 15.30 Image guided minimally invasive procedures – Focal
15.30 – 15.45 Stereotactic ablative radiotherapy for primary renal cancer
15.45 – 16.00 Discussion
16.00 – 16.15 Locally advanced-high risk renal cell carcinoma in the neoadjuvant/adjuvant therapy ARENA
16.15 – 16.30 Experimental and near term future -molecular imaging-
16.30 – 16.45 Immunogenomics -RCC Integrating immunotherapy with the existing drugs-
16.45 – 17.00 Protein-level biomarkers in determining the prognosis and in developing treatment strategies
17.00 – 17.15 Which direction in diagnosis and treatment are we heading? My vision

 

Workshop

17.00 – 18.00 Course-1

Location: Room 2

 

June 29th, 2018
08.00 – 09.00 Opening Remarks
 

Perspectives

Location: Main Hall

09.00 – 10.00 Localised Disease
09.00 – 09.15 When biopsy with mp-MRI?
09.15 – 09.30 mp-MRI in Active Surveillance
09.30 – 09.45 Stereotactic radiotherapy for localized prostate cancer
09.45 – 10.00 Focal therapy: From patient selection to outcomes
 
10.00 – 11.00 Locally Advanced-Oligometastatic
10.00 – 10.15 Imaging in locally advanced and oligometastatic prostate cancer
10.15 – 10.30 Urologist Perspective
10.30 – 10.45 Radiation oncologist perspective
10.45 – 11.00 Regional LNs in prostate cancer: All aspects
 
11.00 – 11.30 Coffee Break
 
11.30 – 12.30 Metastatic Disease – Castration-Resistant Prostate Cancer
11.30 – 11.45 PSMA based imaging and radioligand treatment
11.45 – 12.00 What Combination Drugs with Radium-223 Are Best for Treating Prostate Cancer?
12.00 – 12.15 Conundrums in CHAARTED, LATITUDE and STAMPEDE clinical trials
12.15 – 12.30 Changing role of agents targeting adrenal androgen synthesis.
 
12.30 – 14.00 Lunch
 
14.00 – 15.00 Panel: Role of local radiation therapy/surgery in metastatic setting
 
15.00 – 16.00 Panel: Rising PSA treated with Radiotherapy/ Radical Prostatectomy
 
16.00 – 16.30 Coffee Break
   
16.30 – 17.45 Regional Societies Session
16.30 – 16.45 Immigrants: How to provide care for each patient?
16.45 – 17.00 WHO perspective
17.00 – 17.15 Racial/Ethnic/Socioeconomic Disparities (AD/Targeted/Chemo)
17.15 – 17.30 Cancer stage distribution in the immigrant and host populations
17.30 – 17.45 Genetic variants in different populations
17.30 – 17.45 EBU beyond Europe
 

Young Urooncologists

Residents Meet Masters

Location: Room 2

16.00-16.50 Opportunities
16:00-16:10 Residency training and development in TAU
16:10-16.20 Residency training and development in USA
16:20-16:30 Residency training and development in EAU
16:30-16:40 Residency training and development in SIU
16:40-16:50 What is EUA planning for the residents?
 
17.00-18.00 Education
17:00-17:15 Fundamentals of laparoscopy and education of residents
17:15-17:30 Fundamentals of Robotic Urology and Resident education
17:30-17:45 How to Write a paper?
17:45-18:00 The path, residency to mastership
 

Stay Connected

Location: Room 6

16.00-18.00 Stay Connected
  Prostate Cancer
  Bladder Cancer
  Testis Tumors
  UTT
  Renal Cancer
 

Workshop

16.00 – 18.00 Course-2

Location: Room 3

16.00 – 18.00 Course-3

Location: Room 4

16.00 – 18.00 Course-4

Location: Room 5

 

June 30th, 2018

Perspectives

Location: Main Hall

08.00 – 09.30 Localised Renal Cancer
08.00 – 08.15 Modern Imaging of Renal Tumors 
08.15 – 08.30 The Role of Lymph Node Dissection in the Management of Renal Cell Carcinoma
08.30 – 09.30 Adjuvant Therapy for RCC – Current situation and upcoming trials 
 
09.30 – 10.15 Oligometastastic – Metastatic Disease
09.30 – 09.45 What should be the next step?
09.45 – 10.00 Late-Relapse mRCC
10.00 – 10.15 Absence of complete response
 
10.15 – 10.30 Coffee Break
 
10.30 – 11.30 Panel: Muscle invasive bladder cancer
Radical cytectomy
Chemotherapy
Bladder preservation strategies
 
11:30 – 12:05 Session
11.30 – 11.45 UTT: New Standards
11.45 – 12.05 The Endourological Society President’s Lecture
 
12.05 – 13.00 Lunch
 
13.00 – 14.00 Pediatric Urooncology Update:  Case-Based Panel Discussion
14.00 – 15.00 Disasters of Masters
 

AS – LIVE

Location: Main Hall

15.00 – 15.20 Image guided surgery prostate/kidney
15.20 – 15.40 Perineal Prostatectomy
15.40 – 16.00 Robotic Assisted Perineal Prostatectomy
16.00 – 16.20 UTT endoscopic management
16.20 – 16.40 UTT endoscopic management
16.40 – 16.50  RALP in large prostates
16.50 – 17.00  Blader Cancer –enucleation-
17.00 – 17.40 Partial Nephrectomy Clampless
– Yes
– No
   

Urooncology

Location: Room 1

15:00 – 15:45 Advanced Bladder Cancer
15.00 – 15.15 Immunotherapy in Bladder Cancer: Update
15.15 – 15.30 Chemotherapy moving forward in combination with immunotherapy
15.30 – 15.45 Bladder Cancer BioMarkers: Optimal Utilization for Diagnosis and Recurrence
 

Workshop

16.00 – 18.00 Course-5

Location: Room 2

16.00 – 18.00 Course-6

Location: Room 3

 

July 1st, 2018
08.00 – 09.00 Take home messages

Location: Main Hall

 

 

General Information

Congress Name

8th Eurasian Uro-oncology Congress

Date

June 28th – July 1st, 2018

Congress Language

Turkish-English (Simultaneous translation will be available)

Venue

The Biltmore Hotel Tbilisi – Georgia

Certificates

Certificate of participation will be given to participants on June 30, 2018 through registration desks at congress center.

Badges

The name badges must be worn at all times to access the sessions, social events. The participant, who have pre-registered, will be able to get their prepared badges and other documents during pre-registration without waiting. After completing the registration process, participants can take their badges..

Invitation

At the request of the participants, the official invitation letter will be sent by the Organizing Committee of the Congress.